Free Trial
NYSE:ENOV

Enovis Q3 2026 Earnings Date & Estimates

Enovis logo
$18.25 +0.56 (+3.17%)
Closing price 10/12/2026 03:59 PM Eastern
Extended Trading
$18.26 +0.01 (+0.05%)
As of 10/12/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enovis is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET

What Analysts Expect from Enovis in Q3 2026

Enovis is expected to post earnings of $0.7670 per share on revenue of $557.15 million. In the same quarter a year earlier Enovis reported $0.75 per share on revenue of $548.91 million. Enovis last reported on August 6, 2026, posting $0.90 per share and beating the $0.8470 consensus estimate. Enovis has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.7670
Expected Revenue
$557.15 million
Prior-Year EPS
$0.75
Prior-Year Revenue
$548.91 million
Expected EPS Growth
+2.3%
Expected Revenue Growth
+1.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.90 (Beat by +$0.0530)
Last Quarter Revenue
$582.78 million
EPS Beat Rate
8 of last 8 quarters

Enovis Q3 2026 Earnings FAQ

Enovis (NYSE:ENOV) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Enovis' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Enovis to post earnings of $0.7670 per share for Q3 2026.

The consensus revenue estimate for Enovis is $557.15 million for Q3 2026.

Enovis Earnings Headlines

Is Enovis (ENOV) Stock Cheap After Reaffirming 2026 Guidance?
Enovis (NYSE:ENOV) Stock Rating Cut to "Hold" at Wall Street Zen
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Enovis stock hits 52-week low at 17.29 USD
See More Enovis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enovis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enovis and other key companies, straight to your email.

About Enovis

Enovis (NYSE:ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies. Enovis markets products under established brands including DJO, Aircast, Chattanooga and Mueller, among others.

Enovis was formed through the transformation of Colfax Corporation and adopted its current name in 2022 after the separation of Colfax’s fabrication technology business, which became ESAB Corporation. The company serves customers in North America, Europe and other international markets through direct sales, distributors and healthcare channels. Mark Thierer serves as president and chief executive officer.

View Enovis Profile